Clinical bottom line
Hepatic hydrothorax (HH) is a challenging complication of cirrhosis characterized by transudative pleural effusion, typically right-sided, resulting from diaphragmatic defects allowing ascitic fluid to enter the pleural space. Management remains complex, balancing symptomatic relief with risks of interventions. Recent evidence supports a stepwise approach beginning with sodium restriction and diuretics, progressing to therapeutic thoracentesis for symptomatic relief, and considering transjugular intrahepatic portosystemic shunt (TIPS) in refractory cases. Pleurodesis and indwelling pleural catheters may be options for select patients but carry risks and require careful patient selection. Liver transplantation remains the definitive treatment. This digest summarizes current evidence to inform clinical decision-making in HH management.
What the evidence shows
Conservative management with sodium restriction and diuretics remains first-line for HH, mirroring ascites treatment (Orman et al., 2025). However, HH often responds less favorably due to pleural fluid dynamics and diaphragmatic defects. Therapeutic thoracentesis provides symptomatic relief but is associated with risks including pneumothorax and infection; thus, it is reserved for severe dyspnea or respiratory compromise (Gilbert et al., 2022).
TIPS has emerged as a key intervention for refractory HH, reducing portal hypertension and pleural fluid accumulation. Boike et al. (2022) provide North American practice-based recommendations endorsing TIPS in patients with refractory HH who are suitable candidates, noting improved symptom control and reduced need for repeated thoracentesis. Cottone et al. (2010) also support TIPS efficacy in symptomatic refractory HH, though patient selection is critical due to risks of hepatic encephalopathy and liver function deterioration.
Pleurodesis, using agents such as talc or tigecycline, has been explored as a nonsurgical option for refractory HH. Chaudhary et al. (2016) reported talc pleurodesis as effective in selected cirrhotic patients with refractory HH, achieving symptomatic control but with variable success rates and potential complications. Similarly, Yilmaz et al. (2015) described tigecycline pleurodesis as a feasible alternative, though data remain limited and largely from small case series.
Pippard et al. (2022) provide a comprehensive narrative review emphasizing that pleural interventions should be individualized, considering patient comorbidities and transplant candidacy. Jackson et al. (2021) highlight the importance of multidisciplinary care and early referral for liver transplantation evaluation, as definitive management of HH requires addressing underlying liver disease.
Caveats and uncertainty
Most evidence derives from observational studies, case series, and expert consensus rather than large randomized controlled trials, limiting the strength of recommendations. The heterogeneity of patient populations, variability in liver disease severity, and procedural expertise influence outcomes. TIPS carries significant risks, including hepatic encephalopathy, and is contraindicated in advanced liver failure or cardiac dysfunction. Pleurodesis efficacy is inconsistent, and procedural risks such as infection and respiratory compromise warrant caution.
Data on novel pleurodesis agents like tigecycline are sparse and require validation in larger cohorts. The optimal timing for interventions and integration with liver transplantation pathways remain areas of uncertainty. Additionally, management strategies must be tailored to individual patient goals, comorbidities, and transplant eligibility.
How this may change practice
Clinicians should maintain a high index of suspicion for HH in cirrhotic patients presenting with dyspnea and pleural effusion, confirming diagnosis with pleural fluid analysis. Initial management aligns with ascites treatment principles, emphasizing sodium restriction and diuretics. Therapeutic thoracentesis remains important for symptom relief but should be judiciously applied.
For refractory HH, early multidisciplinary evaluation including hepatology, interventional radiology, and transplant teams is crucial. TIPS should be considered in appropriate candidates to reduce portal pressure and pleural effusion burden, potentially decreasing hospitalizations and improving quality of life. Pleurodesis may be reserved for patients ineligible for TIPS or transplantation, with careful risk-benefit assessment.
This evidence underscores the need for individualized, stepwise management strategies integrating evolving procedural options and transplant evaluation to optimize outcomes in HH.